The adoption of the same standards and protocols by all the Member States will enable the competent authorities to arrive at their decisions on the basis of uniform tests and by reference to uniform criteria and will therefore help to avoid differences in evaluation.
Recital 11, Directive (EU) 2001/83
Judgment of the Court of First Instance (Second Chamber, extended composition) of 26 November 2002. Artegodan GmbH and Others v Commission oDecision
It should be noted that, in any evaluation of a medicinal product, the degree of harmfulness which the competent authority may regard as acceptable depends, in practical terms, on the benefits which the medicinal product is deemed to …
26 Nov 2002 · 62000TJ0074
Opinion of Advocate General Jääskinen delivered on 29 September 2011. European Commission v Republic of Poland.Decision
More precisely, the aim of the marketing authorisation requirement in Article 6(1) of Directive 2001/83 is to guarantee that the potential risks of products are outweighed by their therapeutic efficacy, which is assessed on the basis of …
29 Sep 2011 · 62010CC0185